MarketCapExport financials
Harvard Bioscience (HBIO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Harvard Bioscience Balance Sheet 2025-2008 | HBIO
Brief overview of Harvard Bioscience's assets and capital
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Assets finished at $80.1 million versus $162.3 million initially, losing -50.7%. The balance sheet contracted.
Liabilities expanded faster than the asset base, -16% versus -50.7%. Debt-service capacity deserves attention.
The equity ratio equals 17.2%, with a starting level of 51.4%. Stable cash flow is important under this structure.
The net-debt-to-equity ratio reached 2.1x. High leverage materially limits financial flexibility.
Cash equals 10.8% of the balance sheet, compared with 4.8% five periods ago. This is the readily available cushion.
Retained earnings remain negative at -$214.7 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Conclusion
Harvard Bioscience's financial structure calls for caution. Stronger equity, lower debt or restored liquidity would be needed to improve it.
Annual Balance Sheet Harvard Bioscience
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
28.8 M | - | 27.8 M | 40.6 M | 39.4 M | 39.7 M | 45.5 M | 52.6 M | 6.02 M | 8.15 M | 12.2 M | 7.32 M | -1.02 M | -7.73 M | -1.62 M | -1.7 M | - | - |
Long Term Debt |
35.9 M | - | 30.7 M | 43 M | 45.1 M | 46.3 M | 46.9 M | 58.8 M | 8.98 M | 11.4 M | 16.4 M | 16.4 M | 19.8 M | 13 M | 16.3 M | 18 M | - | - |
Long Term Debt Current |
1.52 M | 1.16 M | 1.42 M | 2.14 M | 2.14 M | 2.11 M | 2.42 M | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 58.5 M | 57.9 M | 64.4 M | 14.4 M | 21 M | 23.2 M | 22.3 M | 24.9 M | 19.4 M | 21.6 M | - | - | - |
Total Current Liabilities |
22 M | 55 M | 26.5 M | 23.2 M | 25.3 M | 21.1 M | 25.3 M | 21.5 M | 14 M | 14.6 M | 19.4 M | 18.1 M | 16.1 M | 9.9 M | 9.56 M | 11.3 M | - | - |
Total Liabilities |
66.3 M | 63.3 M | 64.3 M | 73.1 M | 78.9 M | 79.6 M | 83.2 M | 85.9 M | 28.5 M | 35.6 M | 42.6 M | 40.4 M | 41 M | 29.3 M | 31.1 M | 34.5 M | - | - |
Deferred Revenue |
3.45 M | 3.81 M | 4.51 M | 3.37 M | 4.27 M | 3.77 M | 3.95 M | 4.19 M | 633 K | 500 K | 752 K | 655 K | 640 K | 482 K | 483 K | 451 K | - | - |
Retained Earnings |
-215 M | -158 M | -146 M | -142 M | -133 M | -132 M | -125 M | -120 M | -117 M | -116 M | -112 M | -92.7 M | -95 M | -77.3 M | -79.6 M | -83.4 M | - | - |
Total Assets |
80.1 M | 127 M | 137 M | 145 M | 162 M | 156 M | 165 M | 169 M | 109 M | 108 M | 120 M | 136 M | 135 M | 133 M | 127 M | 125 M | - | - |
Cash and Cash Equivalents |
8.61 M | 4.11 M | 4.28 M | 4.51 M | 7.82 M | 8.32 M | 8.34 M | 8.17 M | 5.19 M | 5.6 M | 6.74 M | 14.1 M | 25.8 M | 20.7 M | 17.9 M | 19.7 M | 16.6 M | 13.7 M |
Book Value |
13.7 M | 63.3 M | 73.1 M | 72.2 M | 83.4 M | 76.7 M | 81.7 M | 82.7 M | 80.9 M | 72.2 M | 77.6 M | 95.5 M | 94.5 M | 104 M | 95.5 M | 90.2 M | - | - |
Total Shareholders Equity |
13.7 M | 63.3 M | 73.1 M | 72.2 M | 83.4 M | 76.7 M | 81.7 M | 82.7 M | 80.9 M | 72.2 M | 77.6 M | 95.5 M | 94.5 M | 104 M | 95.5 M | 90.2 M | 75.3 M | 66.7 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Harvard Bioscience
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
6.88 M | 36.2 M | 6.38 M | 34 M | 34.9 M | 36.4 M | 37 M | 34.3 M | 32 M | 31.9 M | 30.7 M | 35.3 M | 38.2 M | 41.1 M | 43 M | - | - | 46.2 M | 45.1 M | 42.7 M | 40.9 M | 41.6 M | 46.3 M | 46.3 M | 46.3 M | 46.3 M | 46.9 M | 46.9 M | 46.9 M | 46.9 M | 54.8 M | 54.8 M | 54.8 M | 54.8 M | 8.98 M | 8.98 M | 8.98 M | 8.98 M | 11.4 M | 11.4 M | 11.4 M | 11.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 19.8 M | 19.8 M | 21.2 M | 19.8 M | 13 M | 13 M | 13 M | 13 M | 16.3 M | 16.3 M | 16.3 M | - |
Total Liabilities |
66.3 M | 67.9 M | 63.3 M | 63.9 M | 64.4 M | 65 M | 63.3 M | 65.9 M | 61.7 M | 64.3 M | 64.3 M | 65.4 M | 67.5 M | 71.2 M | 73.1 M | - | - | 81.7 M | 78.9 M | 77 M | 75.3 M | 74.1 M | 79.6 M | 79.6 M | 79.6 M | 79.6 M | 83.2 M | 83.2 M | 83.2 M | 83.2 M | 85.9 M | 85.9 M | 85.9 M | 85.9 M | 28.5 M | 28.5 M | 28.5 M | 28.5 M | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 40.4 M | 40.4 M | 40.4 M | 40.4 M | 41 M | 41 M | 40.7 M | 41 M | 29.3 M | 29.3 M | 29.3 M | 29.3 M | 31.1 M | 31.1 M | 31.1 M | - |
Deferred Revenue |
3.45 M | 3.67 M | 3.81 M | 2.88 M | 3.14 M | 3.43 M | 3.81 M | 3.69 M | 4.01 M | 4.39 M | 4.51 M | 4 M | 3.84 M | 4.12 M | 3.37 M | - | - | 3.96 M | 4.27 M | 3.62 M | 3.68 M | 3.64 M | 3.77 M | 3.77 M | 3.77 M | 3.77 M | 3.95 M | 3.55 M | 3.53 M | 3.72 M | 3.82 M | 3.27 M | 3.82 M | 3.82 M | 505 K | 505 K | 505 K | 505 K | 500 K | 500 K | 500 K | 500 K | 752 K | 752 K | 752 K | 752 K | 655 K | 655 K | 655 K | 655 K | 640 K | 640 K | 740 K | 640 K | 482 K | 482 K | 482 K | 482 K | 483 K | 483 K | 483 K | - |
Retained Earnings |
-215 M | -218 M | -158 M | -212 M | -211 M | -208 M | -158 M | -158 M | -153 M | -150 M | -146 M | -144 M | -143 M | -142 M | -142 M | - | - | -140 M | -133 M | -134 M | -133 M | -133 M | -132 M | -132 M | -132 M | -132 M | -125 M | -125 M | -125 M | -125 M | -120 M | -120 M | -120 M | -120 M | -117 M | -117 M | -117 M | -117 M | -116 M | -116 M | -116 M | -116 M | -112 M | -112 M | -112 M | -112 M | -92.7 M | -92.7 M | -92.7 M | -92.7 M | -95 M | -95 M | -77.4 M | -95 M | -77.3 M | -77.3 M | -77.3 M | -77.3 M | -79.6 M | -79.6 M | -79.6 M | - |
Total Assets |
80.1 M | 77.9 M | 127 M | 78 M | 80.1 M | 79.8 M | 127 M | 131 M | 129 M | 133 M | 137 M | 140 M | 143 M | 146 M | 145 M | - | - | 158 M | 162 M | 154 M | 154 M | 151 M | 156 M | 156 M | 156 M | 156 M | 165 M | 165 M | 165 M | 165 M | 169 M | 169 M | 169 M | 169 M | 109 M | 109 M | 109 M | 109 M | 108 M | 108 M | 108 M | 108 M | 120 M | 120 M | 120 M | 120 M | 136 M | 136 M | 136 M | 136 M | 135 M | 135 M | 146 M | 135 M | 133 M | 133 M | 133 M | 133 M | 127 M | 127 M | 127 M | - |
Cash and Cash Equivalents |
8.61 M | 7.1 M | 4.11 M | 6.82 M | 7.44 M | 5.55 M | 4.11 M | 4.57 M | 4.05 M | 4.26 M | 4.28 M | 5.34 M | 4.32 M | 3.79 M | 4.51 M | - | - | 5.43 M | 7.82 M | 5.55 M | 6.24 M | 5.82 M | 8.32 M | 8.32 M | 8.32 M | 8.32 M | 8.34 M | 8.34 M | 8.34 M | 8.34 M | 8.17 M | 8.17 M | 8.17 M | 8.17 M | 5.73 M | 5.19 M | 5.19 M | 5.19 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 6.74 M | 6.74 M | 6.74 M | 6.74 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 25.8 M | 25.8 M | 36.9 M | 25.8 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 17.9 M | 17.9 M | 17.9 M | 20.1 M |
Book Value |
13.7 M | 10 M | 63.3 M | 14.1 M | 15.7 M | 14.8 M | 63.3 M | 65.3 M | 67.2 M | 68.8 M | 73.1 M | 74.3 M | 75.4 M | 74.3 M | 72.2 M | - | - | 76.4 M | 83.4 M | 76.9 M | 78.7 M | 77.1 M | 76.7 M | 76.7 M | 76.7 M | 76.7 M | 81.7 M | 81.7 M | 81.7 M | 81.7 M | 82.7 M | 82.7 M | 82.7 M | 82.7 M | 80.9 M | 80.9 M | 80.9 M | 80.9 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 77.6 M | 77.6 M | 77.6 M | 77.6 M | 95.5 M | 95.5 M | 95.5 M | 95.5 M | 94.5 M | 94.5 M | 105 M | 94.5 M | 104 M | 104 M | 104 M | 104 M | 95.5 M | 95.5 M | 95.5 M | - |
Total Shareholders Equity |
63.3 M | 10 M | 73.1 M | 14.1 M | 15.7 M | 14.8 M | 63.3 M | 65.3 M | 67.2 M | 68.8 M | 73.1 M | 74.3 M | 75.4 M | 74.3 M | 72.2 M | 72 M | 77.5 M | 76.4 M | 83.4 M | 76.9 M | 78.7 M | 77.1 M | 76.7 M | 76.7 M | 76.7 M | 76.7 M | 81.7 M | 81.7 M | 81.7 M | 81.7 M | 82.7 M | 82.7 M | 82.7 M | 82.7 M | 80.9 M | 80.9 M | 80.9 M | 80.9 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 77.6 M | 77.6 M | 77.6 M | 77.6 M | 95.5 M | 95.5 M | 95.5 M | 95.5 M | 94.5 M | 94.5 M | 105 M | 94.5 M | 104 M | 104 M | 104 M | 104 M | 95.5 M | 95.5 M | 95.5 M | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Harvard Bioscience, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical instruments
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
BioLife Solutions
BLFS
|
$ 38.61 | 3.51 % | $ 1.84 B |  USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Alcon
ALC
|
$ 63.87 | 1.38 % | $ 31.5 B |  Schweiz |
 |
Becton, Dickinson and Company
BDX
|
$ 188.89 | 0.81 % | $ 54.3 B | USA |
 |
AtriCure
ATRC
|
$ 57.3 | 0.76 % | $ 2.74 B | USA |
 |
Baxter International
BAX
|
$ 24.8 | 0.46 % | $ 12.7 B | USA |
 |
electroCore
ECOR
|
$ 8.2 | 0.06 % | $ 69.6 K | USA |
 |
Glaukos Corporation
GKOS
|
$ 167.89 | 1.44 % | $ 9.6 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
$ 11.05 | 1.38 % | $ 459 M | USA |
 |
Haemonetics Corporation
HAE
|
$ 121.11 | 0.67 % | $ 5.71 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 13.6 | 0.74 % | $ 281 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 106.05 | 0.97 % | $ 3.39 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 420.24 | 0.52 % | $ 150 B | USA |
 |
Repro Med Systems
KRMD
|
$ 3.11 | 3.67 % | $ 144 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 82.62 | 1.31 % | $ 1.87 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.34 | 1.34 % | $ 27.9 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 87.16 | 0.18 % | $ 5.16 B | USA |
 |
Nephros
NEPH
|
$ 3.52 | 0.56 % | $ 37.4 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 22.82 | 0.75 % | $ 3.83 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 46.32 | 7.66 % | $ 3.12 B | USA |
 |
ICU Medical
ICUI
|
$ 162.69 | 0.09 % | $ 4.01 B | USA |
 |
Pro-Dex
PDEX
|
$ 59.82 | 0.04 % | $ 193 B | USA |
 |
Repligen Corporation
RGEN
|
$ 178.2 | 1.58 % | $ 10 M | USA |
 |
ResMed
RMD
|
$ 235.29 | 0.11 % | $ 34.2 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.59 | 0.8 % | $ 17.7 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 21.84 | 1.58 % | $ 1.08 B | USA |
 |
STERIS plc
STE
|
$ 217.26 | 0.64 % | $ 21.3 B | USA |
 |
Stereotaxis
STXS
|
$ 1.05 | 2.7 % | $ 95.5 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 123.29 | 0.35 % | $ 5.5 B | USA |
 |
Utah Medical Products
UTMD
|
$ 74.79 | 0.11 % | $ 242 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.71 | 0.51 % | $ 273 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 374.65 | 0.77 % | $ 27.1 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 8.44 | 0.29 % | $ 1.68 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
The Cooper Companies
COO
|
$ 54.88 | 0.53 % | $ 10.9 B | USA |
 |
Microbot Medical
MBOT
|
$ 0.99 | 0.49 % | $ 45.3 M |  Israel |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |